Ginkgo Bioworks Holdings (DNA) Total Debt (2020 - 2021)
Ginkgo Bioworks Holdings (DNA) reported Total Debt of $631638.0 for Q2 2021, up 304.03% quarter-over-quarter from $156333.0 in Q4 2020.
Ginkgo Bioworks Holdings (DNA) Total Debt (2020 - 2021) Analysis & Trends
Ginkgo Bioworks Holdings has reported Total Debt for 2 years, with the latest figure at $631638.0 in Q2 2021.
- For the quarter ending Q2 2021, Total Debt changed N/A year-over-year to $631638.0; the trailing twelve-month figure through Jun 2021 stood at $631638.0 (changed N/A YoY), and the FY2020 full-year result was $156333.0, changed N/A from the prior year.
- Total Debt for Q2 2021 stood at $631638.0, up from $156333.0 in the prior quarter.
- The five-year high for Total Debt was $631638.0 in Q2 2021, with the low at $156333.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 319.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ginkgo Bioworks Holdings | 546.79 Mn | 546.79 Mn | 16.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 631,638.00 |
| Dec 31, 2020 | 156,333.00 |